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Abstract

Anthrax is an acute infectious disease caused by B. anthracis, a gram-positive and
spore-forming bacterium. Anthrax toxin is a tripartite AB toxin composed of a receptor
binding/pore-forming moiety, protective antigen (PA), and two catalytic moieties, edema factor
(EF) and lethal factor (LF). Anthrax toxin PA binds to cell-surface receptors, where it gets
activated by furin, and assembles into a ring-like heptameric structure. The toxin-receptor
complex is internalized into endosomes where the acidic pH triggers PA pore formation on the
endosomal membrane that translocates the toxin catalytic moieties. Recent study has shown
that anthrax toxin receptors play a critical role in anthrax toxin action. Reduction of the
disulfides of the R2-Ig domain significantly inhibited the release of K+ through the PA pore
formed on the liposomal membranes and the release of K+ through the plasma membranes of
the CHO cells over-expressing ANTRXR2. Disruption of the disulfides in R2-Ig also inhibited
the PA-mediated LFN translocation across the plasma membrane, suggesting that anthrax
toxin cellular internalization and trafficking may be influenced by cellular redox regulators. In
this study, we investigated the role of PDI in the refolding of ANTXR2 in vitro. Purified PDI was
shown to partially summarize the mis-matched disulfide bonds in the recombinant extracellular
domain of ANTXR2, demonstrating that PDI may be involved in the redox regulation of the
receptor disulfide bonds in vivo.
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Chapter 1: Introduction

1.1 Bacillus anthracis
Anthrax is an acute infectious disease caused by B. anthracis, a gram-positive and
spore-forming bacterium. The possibility of using B. anthracis as a biological weapon is
extremely high due to the possibility of the mass preparation and distribution of spores, and the
limited number of approved drugs against it (1). B. anthracis enters the body by inhalation
(inhalational anthrax), ingestion (intestinal anthrax), and direct skin contacts (cutaneous
anthrax) (Figure 1.1). B. anthracis spores, initially consumed by macrophages, germinate
within these cells to become vegetative bacteria and transport to the lymph nodes, where they
multiply and produce the toxins (lethal factor, edema factor and protective antigen). Death
results from high levels of toxins and bacteria. Lethal factor, a zinc metalloprotease, cleaves
the important mitogen-activated protein kinase kinase (MAPKK) and triggers a severe
inflammatory

condition.

Edema

factor,

a

calmodulin-dependent

adenylate

cyclase,

overproduces cAMP (Cyclic adenosine monophosphate) and causes abnormal water retention.
Protective antigen is involved in the entry of the two toxins into the host cell (2).
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Figure 1.1: Pathophysiology of anthrax (2)

1.2 Anthrax toxin
Anthrax toxin is a tripartite AB toxin secreted by virulent strains of the bacterium,
Bacillus anthracis, the causative agent of anthrax. The toxin consists of three different protein
components: lethal factor (LF), a 90 kDa metalloprotease that cleaves MAP kinase kinases
(edema factor (EF), an 89 kDa adenylyl cyclase; and protective antigen (PA), an 83 kDa
binding and translocation component. PA mediates the transport of LF and EF into the cytosol
of target cells, where they exhibit their activities (3,4).
2

1.2.1 Protective antigen (PA)
Protective Antigen (83 kDa protein, 735 amino acids in length) consist of four functional
domains, each one is required for a particular step in the intoxication process. Domain 1,
amino acid residues 1 to 249, contains the proteolytic activation site responsible for the
liberation of the 20 kDa N-terminal fragment, yielding a 63 kDa protein capable of
oligomerizing into ring shaped heptamers.

Domain 2, residues 250 to 487, consists of a β-

barrel core containing a large flexible loop (between residues 302 and 325) that is believed to
be involved in pore formation.

Domain 3, spanning residues 499 to 594, contains a

hydrophobic region believed to be involved in protein-protein interactions that functions
primarily in self association of PA63. Domain 4, spanning residues 595-735, is involved in
receptor binding (5).

1.3 Anthrax receptors
Two cellular receptors that bind to PA83 have been characterized, namely, ANTXR1
(tumor endothelial marker-8) and ANTXR2 (capillary morphogenesis protein 2) (6). Most
human cells appear to express ANTXR2, while ANTXR1 has been reported to be expressed
by human epithelial cells of the lung, skin,intestines, and endothelial cells (26). Both receptors
are type-1 transmembrane proteins and share about 60% sequence identity (7). The two
cellular receptors are composed of von willebrand factor A domain (VWA), also called integrinlike domain (I domain), which binds to PA, and a newly defined immunoglobulin like domain (Ig
domain), a transmembrane domain, and a cytoplasmic domain (8,9).

3

Figure 1.2: ANTXR2 ectodomain is composed of R2-VWA and R2-Ig. A. Schematic of
ANTXR2. ANTXR2 is composed of R2-VWA and R2-Ig, a transmembrane domain, and
a cytoplasmic domain. B. The crystal structure of R2-VWA domain (1SHU) as displayed
in Swiss-PDB-Viewer. Residues Cys175, the Cys39–Cys218 disulfide bond, and Mn2+
ion of MIDAS are shown and labeled. C. Sequence alignment of the ectodomains of R1
and R2. The seven conserved Cys residues are highlighted and numbered in R2.
Identical residues are labeled with asterisk (*) (9).
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PA binds to VWA domain at metal ion-dependent adhesion site (MIDAS) in the
presence of Mn2+, Mg2+ or Zn2+, and ANTXR2 has been shown to also use Ca2+ but with a
higher affinity when liganded by Mg2+. ANTRX2 has a higher affinity for PA binding than
ANTXR1. VWA domain binds to PA receptor binding domain (domain 4) and pore forming
domain (Domain2), suggesting that the receptor plays roles in PA pore formation. The
ANTXR2 ectodomain (VWA domain and Ig domain) has a total of seven cysteine residues with
three in the R2-VWA domain (C39, C175, C218), and four in the R2-Ig domain (C230, C255,
C279, and C315). It has been found that C39 and C218 form a disulfide bond and C175
remains as a free SH group. It has also been predicted that two disulfide bonds are formed in
the Ig domain (9).
1.4 Translocation of LF and EF into cytoplasm
The first step in toxin uptake involves binding of an 83-kDa form of PA (PA83) to a cellsurface receptor, where it subsequently undergoes a cleavage by furin to generate a 63-kDa
PA subunit (PA63). PA63 spontaneously assembles into a ring-like heptameric structure. The
entire toxin-receptor complex is then internalized into the cells through endocytosis. Within the
endosomal compartment, acidification induces conformational changes in the PA heptamer,
which converts PA heptamer into a membrane-spanning pore on the endosomal membranes.
LF and EF are presumably translocated through the PA pore into the cytosol (8,10).
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Figure 1.3: Model of anthrax toxin action. 1. Intoxication starts with the binding of PA
to receptor. 2. PA is cleaved by furin into PA 63 and PA20. 3. PA63 oligomerizes into
heptamer, EF and/or LF binds to the heptamer. 4. The complex is internalized by
receptor mediated indocytosis. 5. Travel to early endosome. 6. Acidification at the late
endosome low pH triggers conversion of prepore to pore. 7. EF/LF is translocated into
the cytosol (11).
Sun et. al. have found that the intact disulfides in the R2-Ig domain are important for
anthrax toxin action. Reduction of the disulfides of the R2-Ig domain significantly inhibited the
release of K+ through the PA pore formed on the liposomal membranes and the release of K+
through the plasma membranes of the CHO cells over-expressing ANTRXR2. Disruption of the
disulfides in R2-Ig also inhibited the PA-mediated LFN translocation across the plasma
membrane (9). The mechanism of anthrax inhibition induced by reduction of the receptor
disulfide bonds is not clear yet.
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An emerging concept is that disulfide bonds in extracellular domains of cell surface
receptros have the potential to function as redox operator switches ( breaking, forming,
exchanging) (20). Reduction, oxidation, and isomerization of the disulfide bonds are regulated
by a number of cellular redox factors, including protein disulfide isomerase (PDI), which is a
member of the thioredoxin oxireductase super family (12). It is also unknown whether or PDI
interacts with anthrax toxin in vivo during intoxication.
It was demonstrated recently that delivery of diphtheria toxin to the cytosol requires
host cellular thioredoxin reductase cell factors. PDI has been implicated in the mediating
reduction of the diphtheria toxin interchain (13). Also, reduction of HIV gp120 is required for
entry into lymphoid cells (14). The cell surface PDI plays roles in the regulation of integrindependent cell adhesion through control of the open and closed conformations of integrin
receptors (15, 16). In this study we will study the role of the redox regulator factor, PDI, which
may affect anthrax toxin-mediated cytotoxicity through regulating the redox states of anthrax
toxin receptors.
1.5 The thioredoxin-like protein family
The name of this protein family is derived from its first member. Thioredoxin was initially
identified as the hydrogen donor of ribonucleotide reductase. Later, further functions of
thioredoxin were found, such as hydrogen donation to sulfate reductase and the redox control
of transcription factors. Thioredoxin-like oxidoreductases share the thioredoxin-like fold, a
central four-stranded β- sheet with three flanking α-helices and the active site motif Cys-XaaXaa-Cys (17).
1.6 Oxidative refolding of proteins in vitro
The in vitro studying of disulfide bond formation during protein refolding has provided key
insights into the process of oxidative protein folding. A few proteins have dominated the
7

studies on disulfide-linked protein refolding in vitro such as bovine pancreatic trypsin inhibitor
(BPTI), and bovine pancreatic ribonuclease A (RNaseA). Oxidative refolding of reduced,
unfolded proteins in vitro without the addition of co-factors are normally slow and, if more than
one pair of disulfide bonds can be formed, may lead to the formation of incorrect disulfide. To
prevent this from happening, low molecular weight thiols in their reduced and oxidized form
(e.g. GSH/GSSG, cysteine/cystine or DTTred/DTTox) have often been added as “Redox
shuffling” reagents. “Redox-shuffling” reagents allow thiol-disulfide exchange reactions in both
directions and increase yield of proteins with correct disulfide bonds through reshuffling of
improper disulfide bonds (18).
1.7 Protein disulfide isomerase(PDI)
Protein disulfide isomerase (PDI) is a ubiquitous redox chaperone belonging to the
thioredoxin oxireductase super family (19).There are around 20 PDI homologues and the
detailed structure and function of eukaryotic PDIs have been covered in recent excellent
reviews (20). PDI is a multifunctional enzyme has been found to be one of the major enzymes
that assists protein folding, catalyzes the formation, reduction, and isomerisation of disulfide
contained proteins in the ER (19). PDIs are found in all eukaryotic species, and expressed in
most tissues and organs (21).
While PDI enzymes are predominantly located in the ER in high concentrations, they
are also present on the cell surface and can be secreted extracellulary (12). The mature form
of human PDI is 491 amino acids, with a molecular weight of about 56 KDa. The multidomain
structure of PDI was recognized from an analysis of its amino acid sequences, which consists
of four domains, a, b, b’ and a’ plus a highly acidic C-terminal extension c and a 19 amino acid
long inter domain linker between b’ and a’ domains named x. PDI contains two thioredoxin-like
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motifs (CXXC) in two separate domains ( a and a’) and an ER retention signal KDEL at the Cterminus (12,19).
The a and a’ domains which contains the active sites are 47% identical with each other
and 27% to thioredoxin. b and b’ domains share 28% identity to each other, but show a very
low sequence relatedness with thioredoxin (21). The active site motifs are involved in
catalyzing the thiol-disulphide exchange reaction; the b domain is important for the overall
structure of the PDI and b’ domain is involved in substrate recognition and binding (19).

Figure 1.4: Domain structure of PDI. a and a’ are the redox-active thioredoxinlike
domain with the active site CXXC, b and b’ are the redoxinactive thioredoxin-like
domain and c domain. Human PDI domain architecture. Numbers indicate domain
boundaries, with residue numbers representing mature human PDI (28).

PDI

acts as a redox-dependent and -independent molecular chaperone (19). PDI

interacts with many misfolded proteins, peptides and some folded proteins, and has a
significant role in ER-associated degradation (15,22). The essential basis for the redox activity
of PDI is the presence of two thioredoxin-like motifs –CGHC and the ability to catalyze the
activity in thiol-disulfide exchange reaction (22, 23). To function as catalysts of protein thioldisulphide exchange, PDI must be able to interact with their substrates. The oxidation of a
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substrate requires the conversion of a disulfide -CGHC- site to a dithiol, while the reduction of
a substrate requires the conversion of a dithiol active site to a disulfide (19,22). Moreover, all of
the thioredoxin-like domains of PDI are required for isomerization reactions that involve
substantial changes in structure in the substrate (23). Isomerization by PDI occurs via two
possible pathways: through direct isomerisation or through cycles of reduction followed by
reoxidation. The presence of two protein-thiol oxidoreductase active sites in PDI probably, at
least in part, accounts for the diversity of functions and specificity of the enzyme (22, 23).

Figure 1.5: Mechanisms of catalysis by PDI. The main thiol redox reactions driven by
PDI on (protein/peptide) substrate containing thiols (23).
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PDI has been suggested to have a molecular chaperone and anti-chaperone activity
(24). A chaperone is a protein that can associate with other proteins to facilitate their transit in
the cell. A chaperone also assists incorrectly folded or unfolded proteins to attain the native
state and the assembly of polypeptide chains into their correct three-dimensional structure
(22,23). PDI, as a chaperone, inhibits the aggregation of misfolded proteins, such as
glyceraldehde-3-phosphate dehydrogenase (GAPDH), rhodanese, and lysozom. Both GAPDH
and rhodanese do not contain disulfide bridges, confirming the non-redox chaperone activity of
PDI (23, 24). The redox-active sites of PDI are not required for its chaperone activity (25, 27).
1.8 Specific aims
Our long term goal is to investigate the roles of cellular redox factors; particularly PDI, in
anthrax toxin-mediated cytotoxicity.This will provide us insights into the mechanism of anthrax
pathogenesis and may lead to the development of effective drugs against anthrax.
Specific aim 1: characterize the role of PDI in renaturation of the extracellular domain of
ANTXR2
In this aim we investigate the roles of PDI in refolding of the extracellular domain of
ANTXR2 in vitro. PDI has an isomerase and chaperone activity. we will test if PDI assists in
the refolding of ANTXR2 protein in vitro through catalyzing the formation of the disulfide bonds.
Specific aim 2: Test the effects of over-expression of PDI on the receptor-mediated
anthrax toxin action.
The gene encoding PDI will be cloned into the expression vector pcDNA3.1 (+) (sigma)
to generate a HA-tagged PDI. The construct will be transiently transected into the CHO-K1
cells, and expression of PDI will be monitored by western blotting using anti-HA antibody.
Effects of PDI over-expression in CHO-K1 cells will be measured using a cytotoxicity assay, in
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which PA translocates the model substrate, LFN-DTA, into the cytosol, where LFN-DTA inhibits
protein synthesis.
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Chapter 2: Materials and methods

2.1 PDI plasmid
The wild type PDI (Swiss Prot ID P07237) was very generously provided by Dr. Narayan.
2.2 Expression and purification of recombinant human PDI
The PDI vector contains a hexa-histidine tag (His-tag) sequence MHHHHHHM. E.coli
BL21(DE3) was taken out from -80cº ( 30 µl aliquots) and thawed on ice for 10 min. 2µl of PDI
plasmid was added into the cells and incubated on ice for 20 min. the transformation tube was
placed into a 42Cº water bath for 45 seconds and then placed back on ice for 5 min. 200 µl of
LB media was added into the cells and incubated at 37cº with shaking at 200 rpm. The cells
were collected at 10000 rpm for 1 min. the pellet was resuspended with 50 µl LB media and
spread onto LB/carb plates and incubated at 37Cº overnight.
The next day, a single colony was picked and grown in 25 ml of LB medium
supplemented with 25 μg/ml of Carbenicillin at 37°c with shaking at 200 rpm for 16 hours. 20ml
of the startup culture was added to 1L LB media supplemented with 100 μg/ml of Carbenicillin
and incubated at 37°c with shaking at 200 rpm, and induced at OD600 of 0.8 for four hours
with 0.5 mM isopropyl β-D-thiogalactoside. Cells were harvested by centrifuging at 10,000 rpm
for 15 min at 4°c and the pellet was suspended into (20 mM Tris-HCl, 300 mM NaCl, 20 mM
Imidazole, pH 8.0 (buffer A), and disrupted with an ultrasonic cell disrupter. Then cells were
then centrifuged at 19,000 rpm for 40 mins at 4°c. Supernatants were loaded on an
immobilized metal affinity column precharged with Ni2+ and equilibrated with buffer A. The
purity of eluted protein fractions was analyzed on Coomassie Brilliant Blue stained sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
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2.3 Electrophoresis Analysis
(SDS-PAGE) was used to analyze protein samples. Discontinuous gels were cast,
consisting of a separating gel at pH 8.8 and a stacking gel at pH 6.8. Typically, 12%
acrylamide was used in the separating gel. Samples were mixed with the sample loading
buffer (1 M Tris-HCl pH 6.8, 40% glycerol, 0.8% SDS, 0.1% w/v bromophenol blue). A
molecular weight marker was used to estimate the molecular weight of each band. Gels were
run at 107 V through the stacking gel, then at 200 V until the dye front ran off the gel. Gels
were stained with Coomassie Blue.
2.4 Measurement of protein concentration
Purified proteins were quantified using a BCA Protein Assay Kit (Thermo Scientific Pierce).
2.5 PDI isomerase assay
R2-ectodomain oligomers was incubated in the oxidation buffer that contained 20mM
Tris, 0.5mM DTTred, 1mM EDTA, and 100mM of DTTox for different time points. To optimize
the refolding rate, different molar ratio of PDI and receptor were used. As a control, the same
reaction was run without PDI. The reaction was incubated at room temperature and then
analyzed by SDS-PAGE.
2.6 Construction of HA-tagged PDI
pcDNA 3.1(+) (Invitrogen) was used for human PDI expression in CHO cells. Nhe1 and
Not1 sites were generated in the hPDI cDNA by PCR. Amplification cycle entails an initial
denaturation at 95°C for 5 mins, followed by 30 cycles of denaturation at 95°C for 45 Seconds,
annealing at 55°C for 45 s, and extension at 72°C for 2 min.
HA tag (TATCCTTATGACGTGCCTGACTATGCCAGCCTGGGAGGACCT) was introduced to
the C terminus of the PDI to monitor the expression using HA antibody.
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Figure 2.1: pcDNA3.1 (+) plasmid (Invitrogen). The hPDI gene is inserted into the
multiple clone site (MCS) between NheI and NotI.

2.7 Cell Culture and Media
Chinese hamster ovary–K1(CHO-K1 cell line) (ATCC) was grown in Ham’s F-12 medium
supplemented with 10% calf serum, 2 mM L-glutamine, 500 units/ml penicillin, 500 units/ml
streptomycin sulfate under a humidified atmosphere with 5% CO2.

2.8 Transient transfection
The day before the assay, CHO cells were seeded in a 6-well plate to 90% confluency
at the time of transfection. 10μl of Lipofectamine® 2000 Reagent was diluted in 250μl DMEM
free serum medium. Different concentrations of PDI plasmid were used to check the
expression levels. Potential effects of PDI over-expression on cell phenotypes were monitored
after 24 hours. 24 hours post transfection; cells were collected using cell scraper, centrifuged
at 1200 rpm for 5 min. After determining the concentration of the whole protein, SDS loading
sample buffer was added to the lysate, and Boiled for 10 min. Samples were applied to SDSPAGE, followed by western blotting using HA antibody (Santa Cruz Biotechnology,INC) to
monitor the expression of PDI.
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2.9 Western blotting
proteins were transferred onto the PVDF membrane in the transfer buffer( 25mM Trizma
Base, 192mM Glycine, 3.5mM SDS, 20% Methanol) for 45 min at 100 volts. Membrane was
incubated with the primary antibody (Anti- HA antibody, Santa Cruz Biotechnology,INC) in 2%
milk solution overnight. After three times wash with 0.5% Tween20 TBS buffer (20mM Tris,
150mM Nacl, 0.5% Tween,) the membrane was incubated with secondary antibody, goat anti
mouse antibody (Santa Cruz Biotechnology,INC), and then washed five times with TBST
buffer. The bands were visualized using SuperSignal West Pico Chemiluminescent Substrate.
2.10 Immunofluorescence of HA-PDI
CHO cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X100 for 15 mins. The permeabilized cells were incubated with a monoclonal mouse anti-HA
antibody. Subsequently, the cells were incubated with the secondary antibodies goat anti
mouse conjugated with Alexa Fluor 488 (green), and visualized under confocal microscope.

2.11 PDI subcellular fractionation
Twenty-four hours post-transfection, CHO cells were harvested and suspended in cold
buffer 1 (250 mM sucrose, 3 mM imidazole, pH 7.4). The cells were centrifuged at 250 x g for 5
min and resuspended in cold buffer 2 (250 mM sucrose, 3 mM imidazole, pH 7.4, 1% protease
inhibitors mixture and 0.5 mM EDTA). The cells were broken by passing 20 times through a
25-gauge 5 ⁄8-inch needle in buffer 2 followed by centrifugation at 250 x g for 5 min at 4 °C.
The post-nuclear supernatant was centrifuged at 100,000 x g for 30 min at 4 °C. The insoluble
fraction (membrane fraction) was dissolved in buffer 2 containing 1% Triton X-100 and mixed
with an equal volume of SDS sample buffer. The fractions were boiled for 10 min and
subjected to SDS-PAGE followed by Western blot analysis.
16

2.12 Preparation of PA protein
BL21 (DE3) cells were transformed with pET22b-PA wide type, and grown in a
BioFlo/CelliGen 115 Fermentor/Bioreactor 2.5L fermentor at 37Cº to OD600 of 1.0. Expression
of the recombinant protein was induced by the addition of 1mM IPTG. The cells were grown for
an additional 3 h at 30Cº and harvested by centrifugation for 10 min at 8000 x g. Proteins were
released from the periplasm by osmotic shock. The cells were resuspended in 20 mM Tris, pH
8.0, 30% glucose and 1 mM EDTA, and incubated at room temperature for 10 min with
continuous stirring. The cells were again harvested by centrifugation, resuspended in ice-cold
5 mM MgSO4 and incubated at 4 Cº for 10 min with constant stirring. After the cells were again
harvested by centrifugation at 8000 x g the periplasmic extract was decanted. The sample was
loaded onto a column packed with Q-Sepharose High Performance (Amersham-Pharmacia,
Piscataway, NJ). Bound proteins were eluted with buffer B (20 mM Tris, pH 8.0, 1M NaCl). The
PA-containing fractions were determined by SDS-PAGE and concentrated down. The PAprotein was loaded onto a Superdex 200 column at flow rate 0.5 ml/min in the gel filtration
buffer (20 mM Tris-HCl, 150 mM NaCl, at a pH of 8.0). . Fractions containing PA were
determined by SDS-PAGE and stored at –80°C.
2.13 Activation of PA
PA was activated by treatment with trypsin, yielding nicked PA (nPA). Trypsin was
added to PA83 (1 mg/ml) at a final trypsin:PA ratio of 1:1000 (w:w). The mixture was incubated
at room temperature for 1 hour.
2.14 LFN- DTA protein purification
pET-15b LFN DTA vector contains a hexa-histidine tag (His-tag) sequence at the N
terminus. The protein was purified as previously stated in PDI purification.
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2.15 Anthrax toxicity
One day before the assay, a 96-well plate to 90% confluency 96-well plate CHO-K1
cells will be transiently transfected with PDI plasmid as previously stated. Two wells will serve
as a control one will be transfected with pcDNA3.1 (+) empty vector (our negative control), and
one is used for mock transfection. Dilutions of purified PA and purified LFN-DTA in cell culture
medium were made to a final concentration of 10–7 M PA and 10-6 to 10–11 M LFN-DTA, and
added to each well, except for the control wells we only added medium alone (no toxin
control), and then incubated for 4 h at 37°C in a cell incubator. Cell viability was assessed
using the CellTiter 96 Aqueous One Solution Cell Proliferation assay as per the manufacturer's
instructions.
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Chapter 3: Results and discussion
3.1 PDI expression and purification
Recombinant human PDI was expressed using the Escherichia coli strain BL21 (DE3).
The plasmid encodes a fusion protein containing the entire human PDI sequence with an Nterminal His6 tag. Recombinant PDI was purified from the soluble fraction of the cell lysate
using Ni- CAMTM HCresin (Sigma), which is a high-capacity nickel-affinity matrix. Bound PDI
was eluted using 500 mM imidazole in 50 mM Tris/HCl, and 300 mM Nacl (pH 8.0) and
collected in 5.0 ml fractions. PDI protein was further clarified by gel filtration using a Superdex
200 column at flow rate 0.5 ml/min in the buffer containing 20 mM Tris-HCl, 150 mM NaCl, at a
pH of 8.0 (Fig 2.4).

Figure 3.1: Expression and purification of human PDI in BL21 (DE3).( A), Lanes 1 is
molecular weight marker, lane 2 is whole cell lysate after inducing with IPTG (WCL),
lane 3 soluble fraction (SF), lane 4 sample before loading into the Ni+ column, lane 5-8
are different fraction. (B), PDI final purification step (gel filtration). Lane 1 is molecular
weight marker, lane 1 is purified PDI.
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3.2 PDI facilitates the refolding of anthrax receptor 2 ectodomain
To investigate whether ANTXR2 is a specific substrate for PDI; we first examined the
oxidative refolding of ANTXR2 ectodomain with purified PDI. ANTXR2 ectodomain soluble
oligomer was incubated in oxidative buffer (20 mM Tris-HCL, and 1mM EDTA) with 0.5 mM
DTT

red

and 100 mM DTTOX in the presence or absence of PDI for different time points (1 h, 2

h, 3 h, and overnight). As shown in (Figure 2.5) PDI facilitates the refolding of ANTXR2 as the
accumulation of the monomer in the PDI treated PDI (Figure 3.2, lanes 2, 4, 5, and 6)
compared to the non-treated PDI protein (Figure 3.2 lanes 1 and 3). For the time titration, we
noticed that 1 hr is enough to see the isomerase activity of PDI. The observation suggests that
ANTXR2 is a specific substrate of PDI for catalyzing disulfide bond formation in vitro.

Figure 3.2: oxidative refolding of ANTXR2 ectodomain with hPDI. Lane 1 and 3
correspond to R2 ectodomain protein without PDI. Each were incubated for 1hr and 2hr
respectively; lanes 2-6, R2 ectodomain in the presence of PDI incubated for 1hr, 2hr,
3hr, and overnight, respectively.
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3.3 PDI displayed a concentration- dependent isomerase activity
Second, we tested the oxidative refolding of ANTXR2 ectodomain with different R2/
hPDI molar ratio. ANTXR2 ectodomain soluble oligomer was incubated in oxidative buffer (20
mM Tris-HCL, and 1mM EDTA) with 0.5 mM DTT red and 100 mM DTTOX in the absence of
PDI or in the presence of PDI with different PDI/R2 molar ratios (0.02, 0.1, 0.2, 0.3, 0.6, 0.8
and 1.0) for 1 hr at room temperature. Figure 3.3 shows that as the concentration of PDI is
increasing, the amount of protein monomer is increasing as well. We concluded that PDI
catalyzes the oxidative refolding of the ANTXR2 ectodomain in a concentration-dependent
manner.

Figure 3.3: oxidative refolding of ANTXR2 ectodomain with different R2/ hPDI molar
ratio. Lane 2 corresponds to R2 ectodomain protein without PDI; lanes 3-9, R2
ectodomain in the presence of PDI at PDI/R2 molar ratios of 0.02, 0.1, 0.2, 0.3, 0.6, 0.8
and 1.0, respectively; lane 10, corresponds to PDI protein.
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3.4 Expression and characterization of HA- PDI in CHO cells
CHO cells were grown in a 6- well plate, and transiently transfected with pcDNA-Ha-PDI
using Lipofectamine reagent (invetrogen). According to the manufacture, cells were
transfected with 2 µg/ml of the pcDNA-Ha-PDI. Transient transfection with 2 µg/ml of the PDI
expression vector elicited cell rounding (Figure 3.4). Due to the Potential effects of PDI overexpression on cell phenotypes when we used a high DNA concentration, we decided to use
different concentrations of PDI plasmid (100 ng/ml, 200 ng/ml, 400 ng/ml, 800 ng/ml, 2 µg/ml)
to check the expression levels and monitor the cells phenotype effect (cell rounding) after 24
hours. We looked to a good PDI expression with less effect on the cells phenotype. We found
that transfection with a high concentration of pcDNA-HA-PDI stimulated a dose-dependent cell
rounding (Figure 3.5).

Figure 3.4: Effects of PDI over-expression on CHO cells phenotype. A, non-transfected
CHO cells; CHO cells were transiently transfected with pcDNA3.1(+)-PDI, image was
taken 24 hrs post-transfection.
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Figure 3.5, shows that 200 ng/ ml, and 400 ng/ml gave us a good expression of PDI as
well as less affects on the cells phenotype. For the further experiments, 200 ng/ ml DNA
concentration of the PDI plasmid will be used.

A

B

Figure 3.5: Expression and characterization of HA-PDI. A, CHO cells were transfected
with HA- PDI at concentration 100 ng/ml, 200 ng/ml, 400 ng/ml, 800 ng/ml, 2 µg/ml,
respectively. At 24 h post-transfection, the whole cell lysates were subjected to SDSPAGE followed by Western blot using anti-HA antibody. B, CHO cells were cotransfected with HA- PDI at concentration 100 ng/ml, 200 ng/ml, 400 ng/ml, 800 ng/ml,
2 µg/ml, respectively. At 24 h post-transfection, the percentage of cell rounding was
calculated under the fluorescent microscope (percentage of cell rounding = rounding
transfected cells/total transfected cells).
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3.5 PDI localization
CHO cells were transiently transfected with pcDNA-HA-PDI, and fixed in 4%
paraformaldehyde in the PBS buffer, and then incubated with the mouse anti-HA antibody.
This was followed by reaction with a secondary antibody, goat anti mouse conjugated with
Alexa Fluor 488 (green). Fluorescence was localized in the nuclear and in the cytoplasm, but
we were not able to see the membrane localization of PDI (Fig 2.9B). Specificity was shown by
using non-transfected CHO cells; no staining was observed (Fig 2.9A). The expression and
cytosolic localization of PDI was further confirmed in fractionation analysis using Anti-HA
antibody (Figure 2.9 C). PDI was found in the cytoplasmic and membrane fractions as well.

C

Figure 3.6: PDI localization. A and B, immunofluorescence of paraformaldehyde-fixed
CHO cells showing cytoplasmic localization. A non-transfected CHO cells, left panel
DAPI , middle panel Alexa Fluor 488 (green), right panel merged. B, CHO cells were
transfected with HA-PDI, left panel DAPI , middle panel Alexa Fluor 488 (green), right
panel merged. C, pCDNA-HA- PDI was transfected into CHO cells. At 24 h posttransfection, the cells were lysed and fractionated into post-nuclear supernatant (P),
membrane (M), and cytosol (C), which was followed by ECL Western blotting using HA
antibody as the primary antibodies.
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3.6 Protein preparation for anthrax toxicity assay
3.6.1 Expression and purification of 1 LFN- DTA
LFN-DTA is a fusion protein composed of the catalytic chain of the diphtheria toxin fused
to the C-terminus of the PA recognition domain of LF (residues 1-255), which binds to the PA63
heptamer and enters cells by the same pathway as EF and LF. pET-15b-LFN-DTA (Addgene)
has His6- tag at the N terminus. LFNDTA was shown to be expressed as a soluble product of
~50 kDa, after a four hour induction, in Escherichia coli BL21 DE3 (Figure 2.9). LF N-DTA
protein was further purified by using size exclusion chromatography.

Figure 3.7: Induction and purification of LFN-DTA protein in BL21 (DE3). (A), First lane
molecular weight marker, lane 2 is whole cell lysate before induction (WCB), lane 3 is
whole cell lysate after induction (WCA), lane 4 is the flow through, lanes 5-10 are
different fractions. (B), LFN DTA final purification step (gel filtration) in a 12% SDSPAGE. First lane is molecular weight marker, lanes 1-4 different fractions.
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3.6 .2 PA83 purification
Recombinant wild-type PA83 was over-expressed in the periplasm of the Escherichia
coli strain, BL21 (DE3). The 83-kDa PA monomer was purified from the periplasm using anion
exchange chromatography.

Figure 3.8: Expression and purification of PA83 protein in BL21 (DE3). A), AKTA
chromatography showing A280 in blue, fractionation aliquots in red, and buffer
conductance Brown. (B), lanes 1- 8 are different fractionations of the purification
process in a 12% SDS-PAGE, last lane (M) is molecular weight marker.
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PA83 protein was further clarified by gel filtration using a Superdex 200 column at flow
rate 0.5 ml/min in the buffer gel filtration buffer (20 mM Tris-HCl, 150 mM NaCl, at pH 8.0).

Figure 3.9: Size Exclusion Chromatography of PA83. (A), AKTA chromatography
showing A280 in blue and fractionation aliquots in red. (B), first lane (M) is molecular
weight marker, lanes B6 – C5 are fractionations of the purification process in a 12%
SDS-PAGE.
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PA83 was digested using the protease trypsin at a final trypsin:PA ratio of 1:1000 (w:w),
and incubated the digested reaction at room temperature for 1 hr. then, will use a 5mL HiTrap
(GE Healthcare) column for Anion Exchange Chromatography (Figure 3.10 A). Fractions
containing PA were determined by SDS-PAGE (Figure 3.10 B).

Figure 3.10: PA83 digestion with trypsin. A, AKTA chromatography showing A280 in blue,
fractionation aliquots in red, elutant gradient concentration in green, and buffer
conductance in brown. B, SDS-PASE analysis of digested PA83, Lane 1, M, molecular
weight markers (in kDa); lane 2, PA83; lane 3, flowthrough; lane 4, elutes of
PA83 digested with trypsin.
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3.7 Anthrax toxicity assay
After we confirmed the expression of the recombinant PDI, we tested the effect of the
anthrax toxin on CHO cells by inhibiting the PA-mediating translocation of the lethal factor LFNDTA. LFN-DTA, is a fusion between diphtheria toxin A-chain (DTA) to the c-terminus of LFN,
which binds to PA63 heptemer and enters the cells by the same pathway as LF/EF. After entry
into the cytosol, DTA catalyzes the ADP-ribosylation of elongation factor-2, which inactivates
the elongation factor, inhibiting protein synthesis and ultimately causing cell death. Cell viability
was estimated using the MTS assay, which measures the reduction of a tetrazolium salt to
formazan by metabolically active cells. We first searched for incubation conditions that would
lead to reduce metabolic activity in CHO K1 cells by LFN-DTA and PA63. Three trials of the
toxicity assay were performed, and we found that exposure of the CHO cells for 4 hours to a
mixture of 10-6 M LFN-DTA and 10-7 M PA63 was sufficient to reduce metabolic activity by 40%
(Figure 2.15).

Figure 3.11: Effects of LFN-DTA on cell viability and cytotoxicity in CHO cells. MTS
colorimetric assay was performed to measure the survival rate of CHO cells after
treatment with PA, and different concentrations of LFN-DTA. Data points represent the
means ± SEM of experiments performed in triplicates.
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3.8 Discussion
Evidence has shown that cellular redox factors play critical roles in pathogen and toxin
entry into the endocytic pathways, particularly through modulating the thiol-dithiol states of
pathogen- and/or host-factors. For instance, cellular entry of diphtheria toxin to the cytosol
requires host cellular thioredoxin reductase cell factor, PDI, which has been found to mediate
the reduction of diphtheria toxin interchain. Also, cholera toxin, botulinum neurotoxins, anthrax
toxin are apparently dependent on the redox states (reduced or oxidized) of the specific
disulfides of either the toxin compounds, or the host receptors. In this study we attempted to
study the role of the redox regulator factor, PDI, which may affect anthrax toxin-mediated
cytotoxicity through regulating the redox states of anthrax toxin receptors. The question this
project addresses is: does PDI involve redox regulation of ANTXR2. Our first goal was to
characterize the role of PDI in renaturation of the extracellular domain of ANTXR2 In vitro, in
which we investigated if PDI can modulate the refolding of the extracellular domain of ANTXR2
protein in vitro through catalyzing the formation of the mis-matched disulfide bonds. We found
that purified PDI partially can convert the oligemeric receptor to the monomeric protein. We
also found that PDI catalyzes the oxidative refolding of the ANTXR2 ectodomain in a
concentration-dependent manner. From these results we concluded that ANTXR2 is a specific
substrate for PDI enzyme in vitro.
Our second goal was to test the effects of over-expression of PDI on the receptormediated anthrax toxin action. PDI is essential for cell viability, therefore gene deletion
approaches can’t be used to studying its role in anthrax toxin action. However, we can upregulate PDI by over-expression of a recombinant PDI, and then measure the LF N-DTA
membrane translocation in the CHO wide type cells. Here, we subcloned the entire PDI gene
into pCDNA3.1(+) vector with a generation of a C–terminus HA tag to monitor the expression
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using anti-HA antibody. We successfully transiently transfected PDI into CHO cells with a good
expression level. We found that over-expression of PDI in CHO cells affected the phenotype of
the cell. We performed a DNA concentration titration to optimize PDI expression and monitor
the potential effects on the phenotype. A concentration of a 200 ng/ ml of the PDI plasmid was
found to be the optimal DNA concentration to give us a good expression with less numbers of
cell rounding.
To study the Effect of PDI over-expression on the toxic activity of LFN-DTA, our first step
was to prepare the PA63, and LFN-DTA proteins. Successful purifications for both proteins were
achieved with a high yield and about 90% purity. LFN-DTA, a fusion between diphtheria toxin
A-chain (DTA) to the C-terminus of LFN, will bind to PA63 heptemer and enters the cells by the
same pathway as LF/EF. After entry into the cytosol, DTA catalyzes the ADP-ribosylation of
elongation factor-2, which inactivates the elongation factor, inhibiting protein synthesis and
ultimately causing cell death. Different LFN-DTA protein molar concentrations(10-6 M, 10-7 M,
10-8 M, 10-9 M, 10-10 M, and 10-11 M) in a combination with a constant concentration of (PA 63)7
were added to CHO cells seeded 24 hours before the assay in the 96- well plate. Cell viability
was estimated using MTS assay. We found that adding a mixture of 10-6 M LFN-DTA and 10-7
M PA63 for 4 hours was sufficient to reduce metabolic activity by 40% of the CHO cells. 4 hours
exposure is enough to cause this metabolic activity reduction.
3.9 Future directions
Studying the Effect of PDI over-expression on the toxic activity of LFN-DTA will be the
next step of this study. Expression of PDI will be induced for 24 hours in CHO cells, following
by incubation with the toxin mixture for 4 hours, and estimation of the cell viability using MTS.
A More accurate method for measuring the LFN –DTA translocation into the cytosol is to
measure the [3H]-leucine incorporation. In this method, after adding the toxin mixture to the
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PDI transfected CHO cells, and incubating them for 4 hours in the cells incubator, the medium
will be replaced with leucine-free F-12 medium supplemented with [3H] leucine and incubated
at 37°C for 1 hour. Incorporation of 3H-Leucine into the cells will be used as an indicator of
protein synthesis.
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Chapter 4: Role of Human gamma interferon-inducible thiol reductase (GILT) in the
Redox Regulation of ANTXR2

4.1 Gamma interferon-inducible thiol reductase (GILT)
GILT was first discovered as a novel IFN γ-inducible protein in the human monocytic
cell line U937. Later, its function as a thiol reductase was described by Arunachalam et al,
where they used

125

I-F(ab’)2 as a substrate. The reduction of F(ab’)2 into Fab heavy and light

chains was analyzed by non-reducing SDS-PAGE followed by autoradiography. The reduction
of F(ab’)2 with GILT was maximal between pH 4.0 and pH 5.0, whereas the spontaneous
reduction of F(ab’)2 by DTT in the absence of GILT, was seen at pH 7.0 (28).
GILT is a unique member of the thioredoxin (thiol reductase) family, because the
reduction of disulfide bonds by the mature form of GILT in vitro proved to be optimal at low pH
(4.0-5.5) and it is the only thiol reductase known to be active at low pH. The majority of
thioredoxin family enzymes catalyze, at a neutral pH, dithiol oxidation, disulfide bond reduction,
and disulfide bond isomerization. In addition, it’s catalytic active site CXXC, does not have the
common active site motif WCGH/PCK (29,30).
GILT is expressed in antigen-presenting cells. It is synthesized as a 35-kDa soluble
glycoprotein. Following transport to MIICs via the mannose-6-phosphate receptor, it is
processed to the 30 kDa mature form by proteolytic cleavage of its N- and C-terminal
propeptides (27, 28). The mature protein is delivered by M-6-P receptors through the endocytic
pathway to late endosomes and lysosomes. At residues 46–49 there is a CXXC motif similar to
the WCGH/PCK motif of proteins in the thioredoxin family (31).
It has been shown that GILT is a critical host factor that facilitates Listeria
monocytogenes infection. L.monocytogenes is actively phagocytosed by macrophages,
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internalized into the phagosome, and secretes haemolysin listeriolysin O (LLO). Since
reduction is required to activate the lytic activity of LLO in vitro, it was found that GILT is
responsible for the reduction and activation of LLO which form pores on the endosomal
membranes that facilitate bacterial escape from the phagosomes to the cytosol. Mice lacking
GILT are resistant to L. monocytogenes infection, suggesting that GILT activates LLO within
the phagosome by the thiol reductase mechanism (32).
4.2 Objectives
Previous work has shown that the intact disulfides in the Ig-like domain of ANTXR2 are
important for the anthrax toxin action. Upon disruption of these disulfide bonds, PA pore
formation and translocation of LF, EF are significantly inhibited, suggesting that disulfides in
the Ig-like domain of ANTXR may regulate anthrax toxin action. In this project we will
investigate the role of the redox regulator factor, GILT, which may affect anthrax toxinmediated cytotoxicity through regulating the redox states of anthrax toxin receptors.
Gamma Interferon-Inducible Thiol Reductase (GILT) is localized in the endosomes and
lysosomes, and shows optimal activity at pH 4.0-5.5, thus it is of interest to know whether or
not GILT interact with anthrax receptors in vivo during intoxication. To test the effects of
over-expression of GILT on anthrax toxin action through redox regulation of ANTXR2,
we will first over-express GILT in COS-1 cells. GILT gene will be cloned into pcDNA3.1(+) to
generate C-terminus HA-tagged protein, and then we will transiently transfect COS-1 cells with
the generated construct. The expression will be monitored by western blotting using HA
antibody, and similarly, the effect of GILT over-expression on anthrax toxin action will be
measured with the cytotoxicity assay, in which PA translocates the model substrate, LFN-DTA,
into the cytosol, where LFN-DTA inhibits protein synthesis.
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4.3 Materials and methods
4.3.1 Construction of HA-tagged GILT
The cDNA GILT sequence encodes the mature form of GILT was cloned into
pcDNA3.1(+) with a generation of HA tag at both the C- and N-terminus to monitor the
expression by HA antibody.
4.3.2 Cell Culture and Media
(Cos-1 cell line) (ATCC) was grown in DMEM medium supplemented with 10% calf
serum, 2 mM L-glutamine, 500 units/ml penicillin, 500 units/ml streptomycin sulfate under a
humidified atmospherewith 5% CO2.
4.3.3 Transient transfection:
The day before the assay, COS-1 cells were seeded in a 6-well plate to 90% confluency
at the time of transfection. 10μl of Lipofectamine® 2000 Reagent was diluted in 250μl DMEM
free serum medium, and combined with GILT plasmids (N- terminus HA- GILT, and Cterminus HA-GILT). 72 hours post transfection; cells were collected using cell scraper,
centrifuged at 1200 rpm for 5 min. After determining the concentration of the whole protein, the
SDS loading sample buffer was added to the lysate, and Boiled for 10 min. Samples were
applied to SDS-PAGE, followed by western blotting using HA antibody (Santa Cruz
Biotechnology,INC) to monitor the expression of GILT.
4.3.4 Western blotting:
The proteins were transferred onto PVDF membrane in the transfer buffer (25mM
Trizma Base, 192mM Glycine, 3.5mM SDS, 20% Methanol) for 30 min at 100 volts. The
membrane was incubated with the primary antibody (Anti- HA antibody, Santa Cruz
Biotechnology,INC) in 2% milk solution overnight. After being washed three times with 0.5%
Tween20 TBS buffer (20mM Tris, 150mM Nacl, 0.5% Tween,) the membrane was incubated
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with secondary antibody, goat anti mouse antibody (Santa Cruz Biotechnology, INC), and then
washed five times with TBST buffer. The bands were visualized using supersignal west pico
chemiluminescent substrate.
4.4 Results and discussion
Precursor GILT is processed to the 30 kDa mature form by proteolytic cleavage of its Nand C-terminal propeptides, thus, we could not check the expression levels of the mature
protein using wild type GILT with a tag to either N- or C- terminus. Therefore, we generated
two constructs to express the mature form of GILT with N- and C- terminus HA-tag to monitor
the expression using anti HA antibody. The reason we made two constructs with C- and Nterminus tag was because we thought that the tag position may affect the expression and the
binding to M-6-P receptors, therefore affecting the localization of GILT.
COS-1 cells were grown in a 6-well plate, and transiently transfected with the GILT
constructs using Lipofectamide reagent. 72 hr post-transfection, cells were collected, lysed,
and analyzed by SDS-PAGE followed by western blot using HA antibody. As shown in Figure
4.1, and as expected, the mature form of GILT was detected in the cells transfected with Nterminal HA-GILT and C-terminal HA-GILT as well. Also, over-expression of GILT showed no
affect on the cells phenotype even after 72 hours of transfection. We concluded that
expression of the mature form of GILT is not affected by the tag position (N- or C- terminus).

Figure 4.1: Over-expression of mature GILT in COS-1 cells.
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4.5 Future studies
Gamma interferon Inducible Lysosomal Thiol reductase (GILT) is an enzyme that
facilitates protein unfolding, which makes the endocytosed protein accessible to further
enzymatic processing by lysosomal/endosomal proteases. In order to study the role of GILT in
the redox regulation of anthrax receptor mediated toxin action, the mature form of GILT was
successfully over-expressed in COS-1 cell line. Further experiments need to be done to check
the localization of GILT. For instance, immunofluorescence using HA antibody to check if GILT
is localized and delivered to the endosomes and lysosomes using endosomal and lysosomal
protein markers.
The effect of the GILT over-expression on the toxic activity of anthrax toxin will be
performed using a combination of the protective antigen and LFN-DTA. LFN-DTA is a fusion
protein that contains the N-terminus of LF and the catalytic subunit of diphtheria toxin. As LF,
LFN-DTA binds to PA(63)7 heptamers, and it requires acidic pH to translocate from an
endosome into the cytosol, where it leads quickly to inhibition of protein synthesis . Inhibition of
cellular protein synthesis is thus a straightforward measure of LFN-DTA entry and
translocation.
Previous data generated using GILT-deficient mice strongly suggests that the role of
GILT is to reduce disulfide bonds of endocytosed protein, which leads to protein unfolding.
Anthrax toxin translocation requires an oxidative environment that favors the receptor disulfide
bond formation, GILT may interact with the receptor and reduce receptor disulfide bonds
resulting in inhibition of the toxin translocation. This project will provide us with insights into the
mechanisms of anthrax pathogenesis and may lead to development of effective drugs against
anthrax.
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Chapter 5: Cloning, Expression, and Purification of Mycobacterium tuberculosis
Secreted Factors EsxG and EsxH

5.1 Introduction
Mycobacterium tuberculosis, the bacterium that causes tuberculosis, still remains a
major global health problem with an estimated 9.4 million new cases and 2-3 million TB related
deaths annually. TB is transmitted by particulates containing Mtb, released from the lungs of
an infected individual through coughing, sneezing, and spitting (33).
M. tuberculosis encodes 23 Esx proteins, EsxA-W, which are generally characterized by
their small size (about 100 residues), the presence of a central WXG motif and their
organisation in pairs within the genome (34). ESAT-6, a 6 kDa early secreted antigenic target,
has received great attention in recent year. ESAT-6 is secreted by a secretion system called
the ESAT-6 system-1 (ESX-1) or type VII secretion system in a 1:1 heterodimeric complex with
10 kDa culture filtrate protein (CFP-10) (35). The system is encoded by the region of difference
1 (RD1) of the mycobacterial genome, and is conserved in M. tuberculosis and closely related
mycobacteria, such as M. marinum and M. bovis. However, it is absent in the genome of the
attenuated vaccine stain Mycobacterium bovis Bacille Calmette-Guérin (BCG). ESAT-6 is
thought to play a role in the spread of Mtb from one macrophage to another (36).
ESX-1 and ESX-5 are thought to play a role in mycobacterial virulence and have been linked
to the bacteria escape from phagosomes, while ESX-3, which encodes the proteins EsxG and
EsxH, is required for optimal in vitro growth of M. tuberculosis and has been associated with
iron and zinc acquisition (34).
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EsxG and EsxH have been shown to form a stable 1:1 heterodimeric complex. The
high resolution structure of the M. tuberculosis EsxG and EsxH complex has been reported
(Figure 5.1). The structure reveals some striking differences in surface features, including a
potential protein interaction site on the surface of the EsxG•EsxH complex. EsxG•EsxH was
also found to contain a specific Zn2+ binding site formed from a cluster of histidine residues on
EsxH. This site may reflect an essential role in zinc ion acquisition, or point to Zn 2+-dependent
regulation of its interaction with functional partner proteins. The surface features of both the
EsxG•EsxH and EsxA•EsxB complexes suggest functions mediated via interactions with one
or more target protein partners (34).

Figure 5.1: Ribbon representations of the backbone topology of the EsxG•EsxH complex,
EsxG shown in red and EsxH in blue (34).

It has been shown that the protein products of EsxG/EsxH form a 1:1 tight complexe,
which is likely to be the functional form of these proteins (34). In order to study the functional
form of EsxG/EsxH proteins (heterocomplex), we need to purify both proteins and mix them to
do further studies on the heterodimer. EsxG and EsxH are expressed as inclusion bodies in E.
coli with a poor expression. Callahan at, el. (2010) utilized a fusion approach to improve the
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expression of WXG100 proteins which resulted in high yields of soluble, recombinant protein.
This fusion approach should dramatically simplify structural and biochemical studies of related
protein pairs from the WXG family (37). Here we used the same approach, in which the EsxG
and EsxH genes are fused together into a single open reading frame by a linker, thrombincleavage site – 9 amino acids.
5.2 Aims
Aim 1:
Purify recombinant Mycobacterium tuberculosis EsxG and EsxH as a fusion protein expressed
in Escherichia coli.
Aim2:
Investigate the membrane activities of EsxG and EsxH heterocomplex using the K+ release
assay on liposomes.
5.3. Materials and methods
5.3.1 Construction of pET -22b- EsxG and EsxH
EsxG and EsxH genes were first amplified separately by PCR using the primers listed in
Table 1, P1 and P2 to amplify EsxG, P3 and P4 to amplify EsxH. for overlap extension, the
PCR products of EsxG and EsxH were mixed and then used as a template for overlap
extension using P1 and P2 primers, in which the two open reading frames were joined into a
single gene; the DNA sequences of the resulting clones were confirmed. The 27-bp linker used
for overlap extension encoded a thrombin-cleavage site – 9 amino acids, GLVPRGSTG.
Fusion products were cloned into pET22b in frame with the vector’s C-terminal 6-His tag, as an
NdeI/XhoI fragment.
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Table .5.1: Primers used for EsxG/H cloning
Name

Primers

TB_GH_P1
TB_GH_P2 5’ gcccgtgctgccgcgcggcaccaggccgaacccggtataggtcgac 3’
TB_GH_P3 5’ cgcgcggcagcacgggcatgtcgcaaatcatgtacaact 3’
TB_GH_P4 5’ catcctcgaggccgccccatttggcgg 3’

EsxG, and EsxH PCR products are about 300 base pair (Figure 5.2 left panel). The
overlap extension PCR resulted in about 600 bp band (Figure 5.2 middle panel). Fusion
products were subcloned into pET-22b an NdeI/XhoI fragment (Figure 5.2 right panel).

Figure 5.2: Construction of EsxG/ EsxH. left panel, electrophoresis result of EsxG and
EsxH amplification (from left to right: DNA marker, 1–4: PCR production of EsxG and
EsxH, respectively. Middle panel, the electrophoresis result of EsxG and EsxH fusion
gene (from left to right: 1: DNA marker, 1, 4: PCR production of EsxG and EsxH). Right
panel, enzymatic result of pET-22b - EsxG/H, NdeI and XhoI digestion.
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5.3.2 Purification of EsxG and EsxH fusion protein
BL21 (DE3) cells were transformed with pET-22B- EsxG/ EsxH were grown in LB media
containing 100 μg/mL carbenicillin. Culture was induced with IPTG (1mM) at OD600 of 0.8 and
incubated for 4 hours at 37°C. Cells were harvested by centrifuging at 10,000 rpm for 15 min at
4°c and the pellet was suspended into (20 mM Tris-HCl, 300 mM NaCl, 20 mM Imidazole, pH
8.0 (buffer A), and disrupted with an ultrasonic cell disrupter. cells were then centrifuged at
19,000 rpm for 40 mins at 4°c. Supernatants were loaded on an immobilized metal affinity
column precharged with Ni2+ and equilibrated with buffer A. The purity of eluted protein
fractions was analyzed on Coomassie Brilliant Blue stained SDS-PAGE. Purified protein was
then quantified using BCA Protein Assay Kit (Thermo Scientific Pierce).
5.3.3 Thrombin digestion
Fusion protein was cleaved site-specifically within the linker by digesting 1 mg of fusion protein
with 1 µg of thrombin overnight at room temperature.
5.3.4 K+ release assay
20mg of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were resuspended in 1mL of
Chloroform and dried in a vaccum overnight. The dried lipid film was rehydrated in a 10mM
Hepes, pH 7.4, 150mM KCl and then subjected to six freeze/thaw cycles using ethanol and dry
ice. The solution was passed 20 times through a 200-nm pore size polycarbonate filter using a
mini extruder. Then the liposomes were desalted using a 5mL HiTrap Desalting Column in the
desalting buffer (20mM Tris HCl pH 8.0, 100mM NaCl). EsxG/EsxH heterocomplex, were
added to a beaker containing 5 ml reaction buffer (10mM Hepes pH 4.0 and 1M NaAc) and
100 μl of prepared liposomes with constant stirring. Release of K+ ions from liposomes was
monitored using a potassium selective electrode and recorded using DATAQ software.
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5.4. Results and discussion
5.4.1 Expression and purification of EsxG and EsxH fusion protein in E.coli
EsxG and EsxH, both are expressed in Escherichia coli as an insoluble protein. To
check the solubility of the fusion protein, a smale-scale preparation of E. coli BL21 (DE3) cells
expressing the recombinant fusion protein (pET22b-EsxG/EsxH) was grown in 50 ml of LB
media and induced with 1mM IPTG for 4 hrs. The bacterial cell pellet was resuspended in 300
µl of lysis buffer. Samples were boiled for 10 min and the recombinant protein was then
analyzed by SDS-PAGE. As shown in (Figure 4.2 A) the fusion protein was expressed as a
soluble protein. The recombinant fusion protein was purified based on the presence of the 6×
His-tag at the C-terminus using Ni-NTA affinity columns. To purify the protein, a large-scale
preparation of BL21 (DE3) cells were transformed with pET-22B- EsxG/ EsxH were grown in
LB media and induced with 1 mm IPTG. The final bacterial cell pellet was lysed and loaded on
the Ni-NTA column. The recombinant fusion protein was eluted and then evaluated by SDSPAGE (Figure 5.3 B). With the Gene fusion approach we were successful in producing a
strong over-expression of the EsxG and EsxH proteins. We got high yields of the soluble,
recombinant protein (more than 40 mg protein / 1 liter of cells) with a purity of >90%.
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Figure 5.3: Induction and expression of EsxG and EsxH fusion protein. A, Lanes 1-3
are whole cell lysate (WCL), soluble fraction, and insoluble fraction, respectively. Lanes
4-6 are samples which have been induced with IPTG, showing WCL, soluble fraction,
and insoluble fraction, respectively. B, purification of EsxG and EsxH fusion protein, lane
1 molecular weight marker, lane 2 WCL after induction, lane 3 flowthrough, lane 4 wash,
lanes 5-7 are elutes.

The purified EsxG and EsxH fusion protein were incubated with thrombin (1 unit/mg of protein)
at RT for 14 hrs. The extent of digestion was >95%, as assessed by SDS PAGE (figure 5.3).

Figure 5.4: Proteolytic cleavage of purified EsxGH into EsxG and EsxH. Lane 1 shows
molecular weight marker, lanes 2-4 are different amount of the digested protein.
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5.4.2 Disruption of liposomal membranes at pH 4.0
To study the protein- membrane interaction we used a KCl rich liposomes in which upon
liposomal membrane disruption a K

+

release could be read using a K+ ion selective electrode.

Different amount of EsxG and EsxH heterocomplex were used (10 µg, 20 µg, 30 µg, 100 µg).
The complex appeared to disrupt the liposomal membrane by the detection of the K+ (Figure
5.4). Previous works in our lab used the same approach to study the ability of mycobacterium
tuberculosis secreted proteins, ESAT 6 and CFP- 10 to cause membrane disruption. They
found that the ESAT 6 and CFP- 10 heterocomplex induced little release of K+ from the
liposomes, while ESAT 6 alone induced a higher release of K+ ions from the liposomes at pH
4.0 (38). Here our results showed that EsxG and EsxH heterocomplex was shown to generate
a K+ reading similar to that of ESAT-6 and CFP-10 heterodimer at pH 4.0.

Figure 5.5: EsxG and EsxH heterocomplex disrupts liposomes by measuring the
release of K+.
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